185490.KQ EyeGene Inc

Healthcare Oil, Gas & Consumable Fuels KOSDAQ
1,705 KRW
Close of Oct 30, 2026
1,182 2,805
Market cap
KRW 73.7B
P/E
-
P/B
1.47x
ROE
-28.7%
Dividend yield
-
Fundamental score
0.7/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 185490.KQ undervalued?

Graham number

The Graham number of EyeGene Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

EyeGene Inc fundamental analysis

4 of 21 checks passed

ROE 0/2

Low return on equity (-28.7%), below 10%.

ROA 0/1

Return on assets (-23.4%) is below the industry median (1.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (19.0%) is above the industry median (1.8%).

Revenue Growth 0/2

Revenue shrank 12.3% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 0/2

Cash covers 0.3 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (1.5x) is above the industry median (0.9x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

EyeGene Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About EyeGene Inc

EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/r…

Full company profile